A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Clinical trial NCT05338619 · UNKNOWN

Trial details

NCT number: NCT05338619
Sponsor: Sung Yong Lee
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Stage III EGFR Positive Non-small Cell Lung Cancer Non-squamous Non-small-cell Lung Cancer

Start date: 2022-06-30
Primary completion: 2026-03-02
Enrollment: 77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.